Catalog No.
DHD14203
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
PEMT, CA 15-3, H23AG, Peanut-reactive urinary mucin, PEM, EMA, Cancer antigen 15-3, MUC-1, Episialin, MUC1-CT, MUC1-beta, Tumor-associated mucin, CD227, Polymorphic epithelial mucin, KL-6, MUC1-alpha, MUC1, PUM, Krebs von den Lungen-6, MUC1-NT, Tumor-associated epithelial membrane antigen, Mucin-1, Breast carcinoma-associated antigen DF3, Carcinoma-associated mucin
Concentration
2.23 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15941
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Cantuzumab
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study, PMID: 12525512
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study, PMID: 18301896
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors, PMID: 15240523
Technology evaluation: cantuzumab mertansine, ImmunoGen, PMID: 15663331
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice, PMID: 14634038
Gateways to clinical trials, PMID: 12616965
Gateways to clinical trials, PMID: 15834452
Gateways to clinical trials, PMID: 15319815
Gateways to clinical trials, PMID: 12808477
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study., PMID:18301896
Gateways to clinical trials., PMID:15834452
Technology evaluation: cantuzumab mertansine, ImmunoGen., PMID:15663331
Gateways to clinical trials., PMID:15319815
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors., PMID:15240523
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice., PMID:14634038
Gateways to clinical trials., PMID:12808477
Gateways to clinical trials., PMID:12616965
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study., PMID:12525512
For research use only. Not for human or drug use.
